Re: First- and second-line treatments for locally advanced renal cell carcinoma
"Different drugs involved but the idea to not look for biomarkers but rather adverse effects to judge the effectiveness of a treatment is, I think, a new idea that showed promise in this study."
Not truly a new idea, but one gaining in traction. Antiangiogenics have long been known to constrict the blood-carry vasculature, producing high blood pressure. The concept of gauging the effectiveness of antiangiogenic by monitoring blood pressure is as old as Avastin. Same same hand-foot syndrome...
They really need to be watchful of both biometrics and emerging (or diminishing) AEs. I suspect the underlying biology will someday reflect the two are closely intertwined.